Overview of a collaborative global effort to address the burden of familial hypercholesterolaemia
Indian Heart J. 2023 Nov 17:S0019-4832(23)00178-5. doi: 10.1016/j.ihj.2023.11.005. Online ahead of print.ABSTRACTThis is an overview of the EAS Familial Hypercholesterolaemia (FH) Studies Collaboration (FHSC) global consortium and registry (established 2015), which broadly addresses the global burden of FH. Eighty-seven National Lead Investigators from 74 countries form this expanding global consortium, and this global registry currently includes pooled data on almost 70,000 participants from participating countries to facilitate FH surveillance. Published first results from this global registry concluded that FH is diagno...
Source: Indian Heart J - November 19, 2023 Category: Cardiology Authors: Alexander R M Lyons Christophe A T Stevens Kanika I Dharmayat Dr Antonio J Vallejo-Vaz Kausik K Ray Source Type: research
Overview of a collaborative global effort to address the burden of familial hypercholesterolaemia
Indian Heart J. 2023 Nov 17:S0019-4832(23)00178-5. doi: 10.1016/j.ihj.2023.11.005. Online ahead of print.ABSTRACTThis is an overview of the EAS Familial Hypercholesterolaemia (FH) Studies Collaboration (FHSC) global consortium and registry (established 2015), which broadly addresses the global burden of FH. Eighty-seven National Lead Investigators from 74 countries form this expanding global consortium, and this global registry currently includes pooled data on almost 70,000 participants from participating countries to facilitate FH surveillance. Published first results from this global registry concluded that FH is diagno...
Source: Indian Heart J - November 19, 2023 Category: Cardiology Authors: Alexander R M Lyons Christophe A T Stevens Kanika I Dharmayat Dr Antonio J Vallejo-Vaz Kausik K Ray Source Type: research
Overview of a collaborative global effort to address the burden of familial hypercholesterolaemia
Indian Heart J. 2023 Nov 17:S0019-4832(23)00178-5. doi: 10.1016/j.ihj.2023.11.005. Online ahead of print.ABSTRACTThis is an overview of the EAS Familial Hypercholesterolaemia (FH) Studies Collaboration (FHSC) global consortium and registry (established 2015), which broadly addresses the global burden of FH. Eighty-seven National Lead Investigators from 74 countries form this expanding global consortium, and this global registry currently includes pooled data on almost 70,000 participants from participating countries to facilitate FH surveillance. Published first results from this global registry concluded that FH is diagno...
Source: Indian Heart J - November 19, 2023 Category: Cardiology Authors: Alexander R M Lyons Christophe A T Stevens Kanika I Dharmayat Dr Antonio J Vallejo-Vaz Kausik K Ray Source Type: research
Overview of a collaborative global effort to address the burden of familial hypercholesterolaemia
Indian Heart J. 2023 Nov 17:S0019-4832(23)00178-5. doi: 10.1016/j.ihj.2023.11.005. Online ahead of print.ABSTRACTThis is an overview of the EAS Familial Hypercholesterolaemia (FH) Studies Collaboration (FHSC) global consortium and registry (established 2015), which broadly addresses the global burden of FH. Eighty-seven National Lead Investigators from 74 countries form this expanding global consortium, and this global registry currently includes pooled data on almost 70,000 participants from participating countries to facilitate FH surveillance. Published first results from this global registry concluded that FH is diagno...
Source: Indian Heart J - November 19, 2023 Category: Cardiology Authors: Alexander R M Lyons Christophe A T Stevens Kanika I Dharmayat Dr Antonio J Vallejo-Vaz Kausik K Ray Source Type: research
Traditional and novel non-statin lipid-lowering drugs
Indian Heart J. 2023 Nov 16:S0019-4832(23)00176-1. doi: 10.1016/j.ihj.2023.11.003. Online ahead of print.ABSTRACTNon-statin drugs find utility in the management of dyslipidaemia in mixed dyslipidaemia, patients with statin intolerance, and when guidelines directed low-density lipoprotein cholesterol (LDL-C) target cannot be achieved despite maximally tolerated statin. The most definite indication of fenofibrate monotherapy is fasting serum triglyceride >500 mg/dl to reduce the risk of acute pancreatitis It offers a modest reduction in cardiovascular events. The statin-ezetimibe combination is commonly used for lipid low...
Source: Indian Heart J - November 18, 2023 Category: Cardiology Authors: Peeyush Jain Source Type: research
Management of triglycerides, non-high density lipoprotein cholesterol and high density lipoprotein cholesterol
Indian Heart J. 2023 Nov 16:S0019-4832(23)00177-3. doi: 10.1016/j.ihj.2023.11.004. Online ahead of print.ABSTRACTDyslipidaemia characterised by elevated total cholesterol/LDL-C, triglyceride or both or decreased HDL-C is an important risk factor for the development of ASCVD. Atherogenic dyslipidaemia characterised by high TG, low HDL-C and elevated small dense LDL (sdLDL) is more prevalent in Asian Indians. Normal level of TG is generally considered as <150 mg/dl. Hypertriglyceridemia is closely associated with obesity, metabolic syndrome and diabetes mellitus. Goals of management of hypertriglyceridemia are to lower th...
Source: Indian Heart J - November 18, 2023 Category: Cardiology Authors: Zachariah Geevar Source Type: research
Dyslipidemia in diabetes
Indian Heart J. 2023 Nov 11:S0019-4832(23)00175-X. doi: 10.1016/j.ihj.2023.11.002. Online ahead of print.ABSTRACTDiabetes mellitus is a metabolic disorder that often predisposes to cardiovascular diseases (CVD). CVD is an important cause of morbidity and mortality in diabetes. The typical diabetic dyslipidaemia is characterized by low HDL cholesterol, high triglycerides with mildly increased or even normal LDL. This attenuated rise in LDL is due to the more atherogenic small dense LDL particles. Genetic factors, obesity, lack of physical activity, alcohol abuse, poorly controlled glucose levels are some of the common risk ...
Source: Indian Heart J - November 13, 2023 Category: Cardiology Authors: Sanjay Kalra Nishant Raizada Source Type: research
Dyslipidemia in diabetes
Indian Heart J. 2023 Nov 11:S0019-4832(23)00175-X. doi: 10.1016/j.ihj.2023.11.002. Online ahead of print.ABSTRACTDiabetes mellitus is a metabolic disorder that often predisposes to cardiovascular diseases (CVD). CVD is an important cause of morbidity and mortality in diabetes. The typical diabetic dyslipidaemia is characterized by low HDL cholesterol, high triglycerides with mildly increased or even normal LDL. This attenuated rise in LDL is due to the more atherogenic small dense LDL particles. Genetic factors, obesity, lack of physical activity, alcohol abuse, poorly controlled glucose levels are some of the common risk ...
Source: Indian Heart J - November 13, 2023 Category: Cardiology Authors: Sanjay Kalra Nishant Raizada Source Type: research
Dyslipidemia in diabetes
Indian Heart J. 2023 Nov 11:S0019-4832(23)00175-X. doi: 10.1016/j.ihj.2023.11.002. Online ahead of print.ABSTRACTDiabetes mellitus is a metabolic disorder that often predisposes to cardiovascular diseases (CVD). CVD is an important cause of morbidity and mortality in diabetes. The typical diabetic dyslipidaemia is characterized by low HDL cholesterol, high triglycerides with mildly increased or even normal LDL. This attenuated rise in LDL is due to the more atherogenic small dense LDL particles. Genetic factors, obesity, lack of physical activity, alcohol abuse, poorly controlled glucose levels are some of the common risk ...
Source: Indian Heart J - November 13, 2023 Category: Cardiology Authors: Sanjay Kalra Nishant Raizada Source Type: research
Dyslipidemia in diabetes
Indian Heart J. 2023 Nov 11:S0019-4832(23)00175-X. doi: 10.1016/j.ihj.2023.11.002. Online ahead of print.ABSTRACTDiabetes mellitus is a metabolic disorder that often predisposes to cardiovascular diseases (CVD). CVD is an important cause of morbidity and mortality in diabetes. The typical diabetic dyslipidaemia is characterized by low HDL cholesterol, high triglycerides with mildly increased or even normal LDL. This attenuated rise in LDL is due to the more atherogenic small dense LDL particles. Genetic factors, obesity, lack of physical activity, alcohol abuse, poorly controlled glucose levels are some of the common risk ...
Source: Indian Heart J - November 13, 2023 Category: Cardiology Authors: Sanjay Kalra Nishant Raizada Source Type: research
Dyslipidemia in diabetes
Indian Heart J. 2023 Nov 11:S0019-4832(23)00175-X. doi: 10.1016/j.ihj.2023.11.002. Online ahead of print.ABSTRACTDiabetes mellitus is a metabolic disorder that often predisposes to cardiovascular diseases (CVD). CVD is an important cause of morbidity and mortality in diabetes. The typical diabetic dyslipidaemia is characterized by low HDL cholesterol, high triglycerides with mildly increased or even normal LDL. This attenuated rise in LDL is due to the more atherogenic small dense LDL particles. Genetic factors, obesity, lack of physical activity, alcohol abuse, poorly controlled glucose levels are some of the common risk ...
Source: Indian Heart J - November 13, 2023 Category: Cardiology Authors: Sanjay Kalra Nishant Raizada Source Type: research
Ultrathin, biodegradable polymer-coated everolimus-eluting stents for patients undergoing percutaneous coronary intervention: Final three-year results of the PERFORM-EVER registry
Indian Heart J. 2023 Nov 9:S0019-4832(23)00173-6. doi: 10.1016/j.ihj.2023.10.009. Online ahead of print.ABSTRACTThe registry reports 3-year safety and clinical performance of the ultrathin strut (60 μm) biodegradable polymer-coated Tetrilimus, an everolimus-eluting stent (EES) (Sahajanand Medical Technologies Limited, India), in 'real-world' patients with coronary artery disease. A total of 815 Tetrilimus EES were implanted in 735 lesions in 594 patients. At 3-year follow-up, primary endpoint (target lesion failure, TLF) was reported in 8.6 % patients, including 2.6 % cardiac deaths, 3.5 % myocardial infarction and 2.6 % ...
Source: Indian Heart J - November 11, 2023 Category: Cardiology Authors: Sridhar Kasturi Srinivas Polasa Mohammad Ali Sowdagar Praveen Kumar Thejanandan Reddy Chaitanya Nichenamatla Shailender Singh Vijay Kumar Reddy Source Type: research
Ultrathin, biodegradable polymer-coated everolimus-eluting stents for patients undergoing percutaneous coronary intervention: Final three-year results of the PERFORM-EVER registry
Indian Heart J. 2023 Nov 9:S0019-4832(23)00173-6. doi: 10.1016/j.ihj.2023.10.009. Online ahead of print.ABSTRACTThe registry reports 3-year safety and clinical performance of the ultrathin strut (60 μm) biodegradable polymer-coated Tetrilimus, an everolimus-eluting stent (EES) (Sahajanand Medical Technologies Limited, India), in 'real-world' patients with coronary artery disease. A total of 815 Tetrilimus EES were implanted in 735 lesions in 594 patients. At 3-year follow-up, primary endpoint (target lesion failure, TLF) was reported in 8.6 % patients, including 2.6 % cardiac deaths, 3.5 % myocardial infarction and 2.6 % ...
Source: Indian Heart J - November 11, 2023 Category: Cardiology Authors: Sridhar Kasturi Srinivas Polasa Mohammad Ali Sowdagar Praveen Kumar Thejanandan Reddy Chaitanya Nichenamatla Shailender Singh Vijay Kumar Reddy Source Type: research
Natural history of coronary stents: 14 year follow-up of drug eluting stents versus bare metal stents
CONCLUSION: In patients with coronary artery disease, the composite endpoint of MACCE for the first year after stenting was significantly lower in patients receiving DES than those receiving BMS; however, at very long term follow-up, the event rates were similar.PMID:37926420 | DOI:10.1016/j.ihj.2023.11.001 (Source: Indian Heart J)
Source: Indian Heart J - November 5, 2023 Category: Cardiology Authors: Rohit Sunil Walse Krishna Kumar Mohanan Nair Ajitkumar Valaparambil Bijulal Sasidharan Harikrishnan Sivadasapillai Jissa Vinoda Thulaseedharan Source Type: research
Natural history of coronary stents: 14 year follow-up of drug eluting stents versus bare metal stents
CONCLUSION: In patients with coronary artery disease, the composite endpoint of MACCE for the first year after stenting was significantly lower in patients receiving DES than those receiving BMS; however, at very long term follow-up, the event rates were similar.PMID:37926420 | DOI:10.1016/j.ihj.2023.11.001 (Source: Indian Heart J)
Source: Indian Heart J - November 5, 2023 Category: Cardiology Authors: Rohit Sunil Walse Krishna Kumar Mohanan Nair Ajitkumar Valaparambil Bijulal Sasidharan Harikrishnan Sivadasapillai Jissa Vinoda Thulaseedharan Source Type: research
